NIH TETRAMER CORE FACILITY (INFECTIOUS DISEASES OTHER THAN HIV/AIDS)

NIH 四聚体核心设施（艾滋病毒/艾滋病以外的传染病）

• 批准号: 10376128
• 负责人: JOHN ALTMAN
• 金额: $ 200.18万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-21 至 2027-03-20
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10376128
• 关键词: AIDS/HIV problem; Basic Science; Communicable Diseases; Communities; Core Facility; Databases; Disease; Immune; Immune response; Major Histocompatibility Complex; Mediating; National Institute of Allergy and Infectious Disease; Prevention; Public Health; Reagent; Research; Research Personnel; Research Support; Therapeutic Agents; United States National Institutes of Health; biomedical resource; improved; novel therapeutics; programs; repository; vaccine development

The National Institute of Allergy and Infectious Diseases (NIAID) supports research on the basic understanding of immune responses leading to the development of vaccines and novel therapeutic agents for the prevention and treatment of infectious and immune-mediated diseases, and improvements in public health. This research includes support of various reagent facilities, repositories, and databases that provide resources for biomedical researchers. As a part of the research program to improve our understanding of the progression, prevention, and treatment of infectious and immune-mediated diseases, the NIAID supports the NIH Major Histocompatibility Complex (MHC) Tetramer Core Facility. This facility provides synthesis and distribution of soluble MHC tetramer reagents to the global research community.

美国国家过敏和传染病研究所 (NIAID) 支持对免疫反应的基本了解的研究，从而开发用于预防和治疗传染病和免疫介导疾病的疫苗和新型治疗剂，并改善公共卫生。这项研究包括对各种试剂设施、存储库和数据库的支持，为生物医学研究人员提供资源。作为提高我们对传染病和免疫介导疾病的进展、预防和治疗的了解的研究计划的一部分，NIAID 支持 NIH 主要组织相容性复合体 (MHC) 四聚体核心设施。该设施向全球研究界提供可溶性 MHC 四聚体试剂的合成和分销。